ZVRA — Zevra Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $253.21m
- $243.49m
- $27.46m
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 12.8 | 13.3 | 28.6 | 10.2 | 27.5 |
Cost of Revenue | |||||
Gross Profit | — | — | — | — | 26.7 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 33.2 | 18.9 | 37 | 52.7 | 77.1 |
Operating Profit | -20.3 | -5.61 | -8.37 | -42.6 | -49.6 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -24.5 | -12.8 | -8.52 | -26.8 | -46 |
Provision for Income Taxes | |||||
Net Income After Taxes | -24.5 | -12.8 | -8.55 | -26.8 | -46 |
Net Income Before Extraordinary Items | |||||
Net Income | -24.5 | -12.8 | -8.55 | -26.8 | -46 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -24.5 | -12.8 | -62.9 | -26.8 | -46 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -13.2 | -3.14 | -1.76 | -0.443 | -1.3 |